Application of proteomics and metabolomics in the study of diabetic kidney disease

doi:10.3877/cma.j.issn.2095-3216.2020.05.009

Abstract

Abstract:

Diabetic kidney disease is one of the most important causes of end-stage renal disease, and has become a major problem in public health in the world. It is a priority to resolve disputes in clinical diagnosis and treatment of the disease. This article reviewed the research progress in the diagnosis and differential diagnosis, disease progression, prognosis judgment, and efficacy evaluation of diabetic kidney disease, by means of proteomics and metabolomics. Besides, it also explained the similarities and differences between the two omics technologies, and prospected the use of proteomics and metabolomics for research of integrated omics and precision medicine in the context of contemporary big data and artificial intelligence.

Key words: Proteomics, Metabolomics, Diabetic kidney disease

Xiaonan Ding, Qiuxia Han, Dong Zhang, Hanyu Zhu. Application of proteomics and metabolomics in the study of diabetic kidney disease[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2020, 09(05): 232-235.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2020.05.009

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2020/V09/I05/232

References 31

[1]	GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the global burden of disease study 2017 [J]. Lancet, 2020, 395(10225): 709-733.
[2]	Doshi S, Friedman A. Diagnosis and management of type 2 diabetic kidney disease [J]. Clin J Am Soc Nephrol, 2017, 12(8): 1366-1373.
[3]	Ma S, Li Y, Ma C, et al. Challenges and advances in the fabrication of monolithic bioseparation materials and their applications in proteomics research [J]. Adv Mater, 2019, 31(50): e1902023.
[4]	Donnelly D, Rawlins C, DeHart C, et al. Best practices and benchmarks for intact protein analysis for top-down mass spectrometry [J]. Nat Methods, 2019, 16(7): 587-594.
[5]	Wishart DS, Feunang YD, Marcu A, et al. HMDB 4.0: the human metabolome database for 2018 [J]. Nucleic Acids Res, 2018, 46(D1): D608-D617.
[6]	Hirao Y, Saito S, Fujinaka H, et al. Proteome profiling of diabetic mellitus patient urine for discovery of biomarkers by comprehensive MS-based proteomics [J]. Proteomes, 2018, 6(1): 9.
[7]	Currie G, Delles C. Urinary proteomics for diagnosis and monitoring of diabetic nephropathy [J]. Curr Diab Rep, 2016, 16(11): 104.
[8]	Thippakorn C, Schaduangrat N, Nantasenamat C. Proteomic and bioinformatic discovery of biomarkers for diabetic nephropathy [J]. EXCLI J, 2018, 17: 312-330.
[9]	Glassock R. Con: kidney biopsy: an irreplaceable tool for patient management in nephrology [J]. Nephrol Dial Transplant, 2015, 30(4): 528-531.
[10]	BenAmeur R, Molina L, Bolvin C, et al. Proteomic approaches for discovering biomarkers of diabetic nephropathy [J]. Nephrol Dial Transplant, 2010, 25(9): 2866-2875.
[11]	Kim HJ, Cho EH, Yoo JH, et al. Proteome analysis of serum from type 2 diabetics with nephropathy [J]. J Proteome Res, 2007, 6(2): 735-743.
[12]	Rossing K, Mischak H, Dakna M, et al. Urinary proteomics in diabetes and CKD [J]. J Am Soc Nephrol, 2008, 19(7): 1283-1290.
[13]	Good D, Zürbig P, Argilés A, et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease [J]. Mol Cell Proteomics, 2010, 9(11): 2424-2437.
[14]	Siwy J, Schanstra J, Argiles A, et al. Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy [J]. Nephrol Dial Transplant, 2014, 29(8): 1563-1570.
[15]	Papale M, Paolo SD, Magistroni R, et al. Urine proteome analysis may allow noninvasive differential diagnosis of diabetic nephropathy [J]. Diabetes Care, 2010, 33(11): 2409-2415.
[16]	Wei PZ, Fung WW, Jackkit CN, et al. Metabolomic changes of human proximal tubular cell line in high glucose environment [J]. Sci Rep, 2019, 9(1): 16617.
[17]	Lagies S, Pichler R, Bork T, et al. Impact of diabetic stress conditions on renal cell metabolome [J]. Cells, 2019, 8(10): 1141.
[18]	Tofte N, Vogelzangs N, Mook-Kanamori D, et al. Plasma metabolomics identifies markers of impaired renal function: a meta-analysis of 3，089 persons with type 2 diabetes [J]. J Clin Endocrinol Metab, 2020, 105(7): dgaa173.
[19]	Sharma K, Karl B, Mathew AV, et al. Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease [J]. J Am Soc Nephrol, 2013, 24(11): 1901-1912.
[20]	Liu JJ, Ghosh S, Kovalik JP, et al. Profiling of plasma metabolites suggests altered mitochondrial fuel usage and remodeling of sphingolipid metabolism in individuals with type 2 diabetes and kidney disease [J]. Kidney Int Rep, 2017, 2(3): 470-480.
[21]	Saulnier B, Feigerlova E, Halimi J, et al. Urinary lysophopholipids are increased in diabetic patients with nephropathy [J]. J Diabetes Complicat, 2017, 31(7): 1103-1108.
[22]	Zhu C, Liang QL, Hu P, et al. Phospholipidomic identification of potential plasma biomarkers associated with type 2 diabetes mellitus and diabetic nephropathy [J]. Talanta, 2011, 85(4): 1711-1720.
[23]	American Diabetes Association. Microvascular complications and foot care: standards of medical care in diabetes-2020 [J]. Diabetes Care, 2020, 43(Suppl 1): S135-S151.
[24]	Cañadas-Garre M, Anderson K, McGoldrick J, et al. Proteomic and metabolomic approaches in the search for biomarkers in chronic kidney disease [J]. J Proteomics, 2019, 193: 93-122.
[25]	Tofte N, Lindhardt M, Adamova K, et al. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial [J]. Lancet Diabetes Endocrinol, 2020, 8(4): 301-312.
[26]	Siwy J, Klein T, Rosler M, et al. Urinary proteomics as a tool to identify kidney responders to dipeptidyl peptidase-4 inhibition: a hypothesis-generating analysis from the MARLINA-T2D trial [J]. Proteomics Clin Appl, 2019, 13(2): e1800144.
[27]	Liu J, Liu S, Wong M, et al. Urinary haptoglobin predicts rapid renal function decline in asians with type 2 diabetes and early kidney disease [J]. J Clin Endocrinol Metab, 2016, 101(10): 3794-3802.
[28]	Vander K, Tempels F, Ismail N, et al. Discovery of early-stage biomarkers for diabetic kidney disease using ms-based metabolomics (FinnDiane study) [J]. Metabolomics, 2012, 8(1): 109-119.
[29]	Xu L, Hu C, Liu Y, et al. Development of a sensitive and quantitative method for the identification of two major furan fatty acids in human plasma [J]. J Lipid Res, 2020, 61(4): 560-569.
[30]	Du Y, Xu B, Deng X, et al. Predictive metabolic signatures for the occurrence and development of diabetic nephropathy and the intervention of Ginkgo biloba leaves extract based on gas or liquid chromatography with mass spectrometry [J]. J Pharm Biomed Anal, 2019, 166: 30-39.
[31]	Karczewski K, Snyder M. Integrative omics for health and disease [J]. Nat Rev Genet, 2018, 19(5): 299-310.

Please choose a citation manager

Content to export